TOGETHER PsA trial IXE+TIRZEPATIDE TZP vs. IXE alone RCT Obese or Overweight PsA IR to <3 bioDMARDs Primary endpoint ≥10% weight & ACR50 wk 36 31.7% IXE+TZP vs. 0.8% for IXE alone ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02) No clear difference by gender/age/BMI/previous DMARDs https://t.co/lFbeb85b9Y